MedTech News
Labcorp Launches First FDA-Cleared Blood Test for Alzheimer’s Disease
BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer’s disease.
Biomerica receives approval in UAE for at-home ulcer test
The company is collaborating with local companies and healthcare providers to distribute the ulcer test.
Genetically modified immune cell could help organ transplant patients who are prone to rejection
A Medical University of South Carolina team reports in Frontiers in Immunology that it has engineered a new type of genetically modified immune cell that can precisely target and neutralize antibody-producing cells complicit in organ rejection.
Scavenger platelets that store DNA could transform cancer screening
Swansea University has helped uncover a surprising new role for platelets—one that could significantly advance early cancer detection.
Bioengineered platform uses bacteria to sneak viruses into tumors
Researchers at Columbia Engineering have built a cancer therapy that makes bacteria and viruses work as a team. In a study published in Nature Biomedical Engineering, the Synthetic Biological Systems Lab shows how their system hides a virus inside a tumor-seeking bacterium, smuggles it past the immune system, and unleashes it inside cancerous tumors.
Missing messenger RNA fragments could be key to new immunotherapy for hard-to-treat brain tumors
A new study, led by researchers at Children’s Hospital of Philadelphia (CHOP), identified tiny pieces of messenger RNA that are missing in pediatric high-grade glioma tumors but not in normal brain tissues.
Scientists discover eight new schizophrenia genes
Researchers have discovered eight new genes associated with schizophrenia, in the largest exome-sequencing study of the disorder ever conducted. The breakthrough, made by scientists at the Centre for Neuropsychiatric Genetics and Genomics (CNGG) at Cardiff University, provides new information and improves the understanding and future treatment development for schizophrenia.
FDA grants breakthrough device designation to SpinaFX’s Triojection system
The FDA has granted breakthrough device designation to SpinaFX Medical’s Triojection system, a minimally invasive treatment for contained lumbar disc herniations.